Masimo touts study of SpHb monitoring tech

Masimo (NSDQ:MASI) today released results from a study which compared the company’s noninvasive SpHb measurement to conventional laboratory HbL measurements for patients undergoing liver transplantation, touting equivalence between the 2 methods. Researchers in the study reported that Masimo’s SpHb monitoring had “clinically acceptable accuracy of hemoglobin measurement [compared] with a standard laboratory device when used during LT,” according to the company. Masimo said that monitoring a patient’s hemoglobin is essential during liver transplants because shifts in blood and fluid can cause graft dysfunction due to hypo-perfusion and tissue hypoxia, and that over-transfusion can cause end organ damage and graft dysfunction. “In prior studies using SpHb monitoring, reductions in blood transfusion were observed and when used with PVi, another Masimo noninvasive measurement, a reduction in 30-day mortality was observed. Dr. Kayhan’s study adds to the evidence that SpHb may be a useful tool during procedures such as liver transplantation,” founder & CEO Joe Kiani said in a press release. Reserachers investigated results from 55 patients undergoing orthotopic liver transplants, with Hb levels analyzed using a Beckman Coulter LH 780 hematology analyzer and Masimo’s Radical-7 Pulse CO-Oximeter and rainbow ReSposable R2-25r and R2-25a sensors. Arterial blood samples were taken 6 times, with 2 draws during each of the 3 phases o...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Blood Management Clinical Trials Diagnostics Masimo Source Type: news